Your browser is no longer supported. Please, upgrade your browser.
Settings
XBIO Xenetic Biosciences, Inc. daily Stock Chart
XBIO [NASD]
Xenetic Biosciences, Inc.
Index- P/E- EPS (ttm)-12.77 Insider Own4.90% Shs Outstand5.70M Perf Week3.31%
Market Cap8.89M Forward P/E- EPS next Y-2.02 Insider Trans- Shs Float4.83M Perf Month11.43%
Income-18.50M PEG- EPS next Q-0.38 Inst Own19.40% Short Float5.57% Perf Quarter5.41%
Sales- P/S- EPS this Y-94.00% Inst Trans-8.14% Short Ratio0.49 Perf Half Y-41.79%
Book/sh4.73 P/B0.33 EPS next Y- ROA-106.80% Target Price2.50 Perf Year-93.84%
Cash/sh2.11 P/C0.74 EPS next 5Y- ROE-148.00% 52W Range0.93 - 39.00 Perf YTD8.33%
Dividend- P/FCF- EPS past 5Y19.40% ROI- 52W High-96.00% Beta2.70
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin- 52W Low67.74% ATR0.15
Employees7 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)57.36 Volatility9.93% 9.93%
OptionableNo Debt/Eq0.00 EPS Q/Q-15.30% Profit Margin- Rel Volume0.71 Prev Close1.57
ShortableYes LT Debt/Eq0.00 EarningsFeb 14 BMO Payout- Avg Volume549.58K Price1.56
Recom2.00 SMA203.86% SMA5014.99% SMA200-69.95% Volume392,222 Change-0.63%
Jan-08-20Initiated Maxim Group Buy $2.50
Jan-14-20 08:35AM  Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology ACCESSWIRE
Nov-15-19 08:30AM  Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update ACCESSWIRE -7.08%
Oct-29-19 07:05AM  Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference ACCESSWIRE
Oct-18-19 11:21AM  Can Xenetic Biosciences (NASDAQ:XBIO) Fund Its Growth Plans? Simply Wall St. -8.15%
Oct-16-19 08:05AM  Xenetic Biosciences, Inc. to Present at BIO Investor Forum ACCESSWIRE +20.62%
Oct-08-19 08:30AM  Xenetic Biosciences, Inc. Provides Business Outlook ACCESSWIRE
Jul-22-19 08:00AM  Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform ACCESSWIRE -30.72%
Jul-17-19 08:45AM  Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering ACCESSWIRE -49.31%
Jul-05-19 01:19PM  Xenetic Biosciences Shares Surge After Biotech Prices Common Stock, Warrant Offering Benzinga +39.20%
Jun-24-19 09:08AM  Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock ACCESSWIRE +28.01%
Jun-20-19 10:24AM  Introducing Xenetic Biosciences (NASDAQ:XBIO), The Stock That Collapsed 98% Simply Wall St.
May-14-19 07:42AM  The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings Benzinga
May-13-19 08:05AM  Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update ACCESSWIRE
May-02-19 07:05AM  Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D. ACCESSWIRE -5.67%
Apr-01-19 07:30AM  Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update ACCESSWIRE
Mar-05-19 09:27AM  Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering ACCESSWIRE
Mar-04-19 08:00AM  Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform ACCESSWIRE -11.24%
Dec-04-18 02:57PM  What Investors Should Know About Xenetic Biosciences Incs (NASDAQ:XBIO) Financial Strength Simply Wall St.
Aug-14-18 11:37PM  Why Xenetic Biosciences Just Surged 28 Percent InvestorPlace -14.95%
08:05AM  Xenetic Biosciences Oncology Phase II Trial in Process, Pipeline Overview ACCESSWIRE
08:00AM  Todays Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma ACCESSWIRE
Jun-25-18 07:30AM  Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock ACCESSWIRE +103.90%
May-25-18 03:29PM  Interested In Xenetic Biosciences Inc (NASDAQ:XBIO)? Heres How It Performed Recently Simply Wall St. -13.71%
Feb-05-18 08:09PM  How Does Xenetic Biosciences Inc (NASDAQ:XBIO) Affect Your Portfolio Returns? Simply Wall St.
Jan-19-18 05:35PM  Xenetic Biosciences Inc (NASDAQ:XBIO): Is Now The Time To Bet On Healthcare? Simply Wall St.
Jan-02-18 04:29PM  Does Xenetic Biosciences Incs (NASDAQ:XBIO) CEO Pay Compared Well With Peers? Simply Wall St.
Dec-08-17 01:53PM  Who Really Owns Xenetic Biosciences Inc (XBIO)? Simply Wall St.
Nov-30-17 07:35PM  Does Xenetic Biosciences Incs (XBIO) 83.8% Earnings Growth Make It An Outperformer? Simply Wall St.
Nov-15-17 07:05AM  Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update Business Wire
Nov-02-17 08:05AM  Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc Business Wire
Oct-31-17 09:05AM  Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer Business Wire
Oct-04-17 01:16PM  How Should You Think About Xenetic Biosciences Incs (XBIO) Risks? Simply Wall St.
Oct-02-17 10:45AM  Xenetic Biosciences Provides Update on Annual Meeting of Stockholders Business Wire
Aug-23-17 08:05AM  Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders Business Wire
Aug-15-17 08:05AM  Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update Business Wire
Aug-14-17 05:00PM  Xenetic Biosciences Announces Appointment of Three Directors to the Board Business Wire
Jul-18-17 04:05PM  Xenetic Biosciences Announces Adjournment of Annual Meeting of Stockholders until Wednesday, August 16, 2017 Business Wire
Jun-26-17 08:35AM  Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy for the Treatment of Endometrial Cancer Business Wire
May-22-17 01:05PM  Shire and tiny Lexington biotech say hemophilia drug trial misses mark American City Business Journals
07:00AM  Xenetic Biosciences Receives Program Update from Partner Shires Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A Business Wire
May-16-17 07:00AM  Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update Business Wire
May-09-17 08:35AM  Xenetic Biosciences to Host 2017 First Quarter Update Conference Call Business Wire
May-01-17 08:30AM  Xenetic Biosciences Presents Case Study of PolyXen Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston Business Wire
Apr-20-17 07:35AM  Xenetic Biosciences PolyXen Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston Business Wire
Apr-04-17 07:30PM  Edited Transcript of XBIO earnings conference call or presentation 4-Apr-17 12:30pm GMT Thomson Reuters StreetEvents
07:30PM  Edited Transcript of XBIO earnings conference call or presentation 4-Apr-17 12:30pm GMT
07:05AM  Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer Business Wire
07:05AM  Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer
Apr-03-17 07:35AM  Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update Business Wire
Mar-31-17 05:10PM  XENETIC BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
09:30AM  Prana Biotechnology and Xenetic Biosciences Expand Their Product Promotion Accesswire
Mar-29-17 10:56AM  Xenetic Biosciences, Inc. (Nasdaq: XBIO) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
07:35AM  Xenetic Biosciences to Ring Nasdaq Stock Market Opening Bell on March 30, 2017 Business Wire
Mar-27-17 08:05AM  Xenetic Biosciences Provides Update on Patent Portfolio Development Business Wire
Mar-09-17 08:00AM  Xenetic Biosciences to Present at the 29th Annual ROTH Conference Business Wire
Feb-27-17 03:49PM  XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Jan-06-17 07:05AM  Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia Business Wire
Jan-04-17 05:27PM  XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Ot
07:35AM  Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer Business Wire
Jan-03-17 07:35AM  Xenetic Biosciences to Present at Biotech Showcase 2017 Business Wire
Dec-20-16 07:16AM  Coverage initiated on Xenetic by Ladenburg Thalmann
Dec-15-16 11:48AM  Shire PLC (ADR) (SHPG) Looks To Xenetic Biosciences Inc (XBIO) To Cement Hemophilia Market Share at Insider Monkey
Dec-06-16 05:20PM  XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Ot
Dec-05-16 07:05AM  Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer Business Wire
Dec-01-16 07:35AM  Xenetic Biosciences to Present at the LD Micro 2016 Annual Conference Business Wire
Nov-23-16 01:04PM  XENETIC BIOSCIENCES, INC. Financials
07:05AM  Xenetic Biosciences to Host Quarterly Update Conference Call and Webcast Business Wire
Nov-22-16 03:23PM  XENETIC BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Ot
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on progressing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.